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Abstract
Context: Hepatic steatosis, defined as increased hepatocellular lipid content (HCL), associates with visceral obesity and
glucose intolerance. As exact HCL quantification by 1H-magnetic resonance spectroscopy (1H-MRS) is not generally
available, various clinical indices are increasingly used to predict steatosis.
Objective: The purpose of this study was to test the accuracy of NAFLD liver fat score (NAFLD-LFS), hepatic steatosis index
(HSI) and fatty liver index (FLI) against 1H-MRS and their relationships with insulin sensitivity and secretion.
Design, Setting and Participants: Ninety-two non-diabetic, predominantly non-obese humans underwent clinical
examination, 1H-MRS and an oral glucose tolerance test (OGTT) to calculate insulin sensitivity and b-cell function. Accuracy
of indices was assessed from the area under the receiver operating characteristic curve (AROC).
Results: Median HCL was 2.49% (0.62;4.23) and correlated with parameters of glycemia across all subjects. NAFLD-LFS, FLI
and HSI yielded AROCs of 0.70, 0.72, and 0.79, respectively, and related positively to HCL, insulin resistance, fasting and post-
load b-cell function normalized for insulin resistance. Upon adjustment for age, sex and HCL, regression analysis revealed
that NAFLD-LFS, FLI and HSI still independently associated with both insulin sensitivity and b-cell function.
Conclusion: The tested indices offer modest efficacy to detect steatosis and cannot substitute for fat quantification by 1H-
MRS. However, all indices might serve as surrogate parameters for liver fat content and also as rough clinical estimates of
abnormal insulin sensitivity and secretion. Further validation in larger collectives such as epidemiological studies is needed.
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Introduction
Hepatic steatosis is the most frequent liver disease in Western
countries, closely associates with insulin resistance, visceral obesity,
dyslipidemia and type 2 diabetes (T2DM) and is now classified
among non-alcoholic fatty liver diseases (NAFLD) in the absence
of excessive alcohol intake [1]. The gold standard for diagnosis of
NAFLD is the liver biopsy, which is only justified in severe liver
disease [2]. 1H-magnetic resonance spectroscopy (1H-MRS) allows
for non-invasive quantification of hepatocellular lipid (HCL)
content and for exact diagnosis of steatosis [2], while ultrasound
and computed tomography provide rather semi-quantitative
estimates [3].
As these techniques are time-consuming, expensive and often
unavailable in daily routine, more simple tests have been
developed based on routine laboratory and anthropometric
parameters. The fatty liver index (FLI) [4], the hepatic steatosis
index (HSI) [5] and the NAFLD liver fat score (NAFLD-LFS) [6]
yielded satisfying results in their respective collectives, when validated
against ultrasound (FLI, HSI) or 1H-MRS (NAFLD-LFS). However,
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despite the association of steatosis with impaired glucose tolerance
[7], FLI and HSI seem to perform less well in insulin resistant states
such as T2DM [8].
We aimed to test (i) the diagnostic accuracy of these three
indices by comparison with exact quantification of HCL by 1H-
MRS and (ii) the relationships with insulin sensitivity and secretion
in a non-diabetic, predominantly non-obese collective of white
origin in which median liver fat content is supposed to be low and
therefore diagnosis of steatosis appears more challenging. Of note,
the FLI has been originally developed to detect steatosis, whereas
HSI and NAFLD-LFS have been developed to detect NAFLD. To
account for these differences, we also analyzed a subgroup of our
collective with low-risk alcohol consumption [9].
Study Population and Methods
Study design
This study was performed in the context of the German
National Cohort feasibility studies. The protocol is in line with the
1975 Declaration of Helsinki and was approved by the Bavarian
Medical Association and the ethical board of Heinrich-Heine
University Du¨sseldorf. All subjects gave their written informed
consent to participate.
Overall, from July to October 2011, 148 residents of the
Du¨sseldorf area, aged 22 to 70 years, were recruited from a
random sample of the general population. 100 persons agreed to
participate in additional clinical examination, blood sampling after
10 hours of fasting, a 2-hours oral glucose tolerance test (OGTT),
liver 1H-MRS and whole-body MR imaging (MRI). Persons with
non-white origin, T2DM and/or with hepatitis B and C were
excluded from analysis, because these conditions are known to
specifically affect HCL [10] so that 92 subjects remained for
further analyses.
Clinical examination
All participants underwent a structured interview including
assessment of mean daily alcohol intake during 7 days using
estimated ethanol contents of beverages (beer 5%, wine 12%, shots
40%). The World Health Organization definition was applied for
low-risk alcohol (LRA) consumption [9].
Body weight was measured to the nearest 0.1 kg using a
calibrated weighting scale (SECA 285; SECA, Hamburg,
Germany). Body height and waist circumference (waist) were
measured according to standard procedures. Values of systolic
(SBP) and diastolic blood pressure (DBP) were measured thrice
after 5 min rest in sitting position using a validated automatic
device (OMRON HEM 705 IT, OMRON, Mannheim, Ger-
many) and means of the last two measurements were used for
analysis.
Oral glucose tolerance test (OGTT)
A 75 g-OGTT (Accu-Chek Dextro O.G-T., Roche, Basel,
Switzerland) was performed after at least 10 hrs overnight fasting.
Blood samples were drawn at 25, 30, 60 and 120 min of OGTT
and dysglycemia was categorized according to international
criteria [11].
Laboratory measurements
Alanine aminotransferase (ALT), aspartate aminotransferase
(AST), c-glutamyl transpeptidase (c-GT) and HDL-cholesterol
(HDL-C) were measured on a Cobas MODULAR analyzer
(Roche, Basel, Switzerland). Triglycerides (TG) were measured on
a Hitachi 912 analyzer (Roche, Basel, Switzerland). Blood glucose
was measured from venous whole blood samples using an EPOS
Analyzer 5060 (Eppendorf, Hamburg, Germany). Insulin was
determined by microparticle enzyme immunoassay (MEIA) on an
AXSYM analyzer (Abbot, Abbot Park, USA), C-peptide (CP) was
measured chemiluminimetrically (Immulite1000, Siemens, Erlan-
gen, Germany).
1H-MRS and MRI
All measurements were performed using a 3-T MR scanner
(Philips achieva, X-series, Eindhoven, Netherlands). For 1H-MRS,
a stimulated echo acquisition mode (STEAM) sequence (repetition
time of 4 s, echo time of 10 ms) was performed on a volume of
36362 cm3 in the liver. Spectra was collected without water
suppression from 32 acquisitions and analyzed using the NUTS
software package (Acorn NMR Inc, Livermore, CA, USA). HCL
was quantified and corrected for T2 relaxation times with specific
weighting for lipids as previously reported [12,13]. Steatosis was
defined as HCL values $5.56% [14]. Whole body MRI was
performed to quantify liver volume (HVOL), total (ATtot),
subcutaneous (SAT) and visceral (VAT) abdominal adipose tissue
using transverse multi-slice turbo-spin echo sequences [15].
Indices of hepatic steatosis
NAFLD liver fat score (NAFLD-LFS) [6].
NAFLD{LFS~-2:89z1:18 MS(yes~1=no~0)
z0:45  T2DM(yes~2=no~0)z0:15  I0
z0:04  AST{0:94  AST=ALT ;
with I0 (mU/ml) representing fasting insulin and AST, fasting AST
levels (U/l). Values #20.640 rule out, while values .20.640 rule
in NAFLD. Metabolic syndrome (MS) was defined according to
the criteria of the International Diabetes Federation [16].
Hepatic steatosis index (HSI) [5].
HSI~8  ALT=ASTzBMIz2, if DM;z2, if female;
with values ,30 ruling out and values .36 ruling in steatosis.
Fatty liver index (FLI) [4].
FLI~logistic(0:953  ln(TG)z0:139  BMI
z0:718  ln(cGT)z0:053  waist{15:745)  100;
where logistic(x) = 1/(1+e-x) denotes the logistic function and ln the
natural logarithm. Values ,30 rule out and values $60 rules in
steatosis.
Index of percentage HCL
NAFLD-LFS_cont [6].
NAFLD{LFS cont(liver fat%)~
10({0:805z0:282MS(yes~1=no~0)z0:078T2DM(yes~2=no~0)z0:525log(I0z0:521log(AST0){0:454log(AST0=ALT))
log denotes the decadic logarithm.
Measures of insulin sensitivity and secretion
QUICKI. For fasting conditions, we applied the quantitative
insulin sensitivity check index (QUICKI) calculated as 1/[log(G0)
+log(I0)], where G0 and I0 are fasting glucose and insulin [17].
OGIS. Dynamic insulin sensitivity was assessed with the oral
glucose insulin sensitivity index (OGIS), derived from a complex
Comparison of Liver Fat Indices
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mathematical model, which represents total glucose disposal or
whole body insulin sensitivity [18].
ISIcomp. The Matsuda’s index (ISIcomp) was used as
another measure of dynamic insulin sensitivity and calculated as
= 10000/!(G06I06Gm6Im), where Gm and Im are mean glucose
and insulin concentrations during OGTT [19].
Fasting b-cell function. During fasting, b-cell function was
calculated as CP0/G0.
Insulinogenic indices (IGI). During glucose loading, the
insulinogenic index was calculated as IGI_Ins = (I30 – I0)/(G30 –
G0), where I30 and G30 are insulin and glucose concentrations at
30 min of OGTT [20,21].
IGI_Ins reflects the appearance of insulin in the peripheral
circulation.
For more precise assessing of b-cell (pancreatic, pre-hepatic)
function, C-peptide levels were used to calculate the IGI_CP as
(CP30 -CP0)/(G30 – G0), where CP0 and CP30 are C-peptide
concentrations at fasting and 30 min of OGTT [21].
Disposition Index (DI). The DI is given as product of
insulin sensitivity (OGIS) with post-hepatic insulin release function
(IGI_Instot) [22,23].
Adaptation Index (AI). The AI is the product of insulin
sensitivity (OGIS) with b-cell function (IGI_CPtot) [24,25].
Hepatic insulin extraction. Hepatic insulin extraction was
approximated by a function of 1–(AUCIns/AUCCP) [26].
Statistical Analyses
The diagnostic performance of the indices was tested by the
area under the receiver operating characteristic curve (AROC)
[27]. Confidence bounds for comparison between AROC’s were
done as described [28]. The Clopper-Pearson method [29] was
used to calculate exact confidence bounds for sensitivity (Se) and
specificity (Sp) at different cut-off limits. The Youden index was
calculated as sum of Se and Sp-1 [30].
Variables with skewed distribution were ln-transformed before
correlation and regression analyses. Moreover, the logit transfor-
mation (logit(x) = ln(x/(1-x)) was applied to the FLI index, divided
by 100, to obtain a corresponding linear (approximately normally
distributed) index given by
FLIl~0:953  ln(TG)z0:139  BMI
z0:718  ln(cGT)z0:053  waist{15:745:
This linear index has identical characteristics (ROC, Se, Sp) as
the original index and was only used for regression analysis, for all
other analyses we applied the original index.
P-values from two-sided tests less than 5% were considered to
indicate statistically significant differences. For comparing two
Table 1. Participants’ characteristics.
No steatosis Steatosis No steatosis +LRA Steatosis +LRA
N (m/f) 75 (29/46) 17 (7/10) 54 (25/29) 11 (6/5)
Age (years) 57.1612.2 59.968.5 56.8613.1 59.769.0
Alcohol (g/d) 18.1616.1 26.1618.8 11.169.7 18.1612.9
BMI (kg/m2) 25.364.1 28.262.8** 25.264.1 27.862.31
Waist (cm) 87.1612.4 94.668.5* 87.0612.3 94.766.611
SBP (mmHg) 121.6615.6 128.1610.3 122.5614.3 129.566.71
DBP (mmHg) 72.5468.7 79.368.0** 71.967.6 80.168.911
TG (mg/dl) 78 [60;117] 109[84;153]* 79[56;110] 125[87;153]1
HDL-C (mg/dl) 68.3617.8 58.1612.7* 67.3618.2 55.7612.71
AST (U/L) 24[21;28] 25[22;32] 24[21;28] 23[21;31]
ALT (U/L) 18[14;25] 26[17;46]** 18[13;24] 26[17;29]1
a˜GT (U/L) 20[14;30] 30[20;35] 21[14;30] 30[20;35]
MS (n) 6 4 3 2
G0 (mg/dl) 75.768.3 77.6610.7 75.567.9 77.269.5
G120 (mg/dl) 89.7621.5 96.7626.0 89.7621.3 92.6627.7
I0 (mU/ml) 6[5;9] 8[6;13]* 6[5;9] 8[6;12]
1
I120 (mU/ml) 37[24;57] 64[38;119]*** 33 [23;57] 67[38;102]
1
Hep_Extr (%) 69[62;74] 60[57;66]** 69[62;73] 59[56;66]11
HCL (%) 1.3[0.4;3.4] 13.6[8.3;22.3] 1.1[0.4;2.9] 11.8[8.3;20.1]
HVOL (L) 1.6[1.4;1.8] 1.8[1.8;1.9]** 1.6[1.4;1.8] 1.8[1.7;1.9]1
ATtot (L) 22[18;29] 29[27;32]*** 22[18;27] 28[24;32]
1
VAT (L) 2.9[1.7;4.4] 4.3[3.3;6.5]** 3.1[1.6;4.4] 4.6[3.3;6.5]111
SAT (L) 5.5[4.4;8.1] 7.4[6.6;9.4] 5.4[4.4;7.4] 7.4[5.6;9.4]
Normally distributed data given as mean6standard deviation; Log-normally distributed data as median [25%quartile;75%quartile];
*p,0.05;
**p,0.01 for steatosis vs no steatosis;
1p,0.05;
11p,0.01,
111p,0.001 for steatosis vs no steatosis in LRA.
doi:10.1371/journal.pone.0094059.t001
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concentration-time curves, we tested specific time points with a
Bonferroni-adjusted multiple t-test controlling the family-wise
error rate at level 5%. All analyses were performed with SAS for
Windows Version 9.2 (SAS Institute, Cary, North Carolina, USA).
Results
Clinical characteristics
Persons with steatosis had higher BMI, waist, DBP, TG, ALT,
fasting and 2-hour insulin but lower HDL-C (Table 1). Those with
steatosis and low risk alcohol consumption (LRA) also had higher
SBP. There were no differences between the respective subgroups
with or without LRA.
HCL ranged from 0.03 to 39.01% (median 2.49%; interquartile
range (0.62;4.23)) across the whole group (Figure S1 A) and from
0.05 to 30.34% (1.47% (0.60;4.02)) in the LRA subgroup. In the
whole group, NAFLD-LFS, HSI and FLI ranged from 24.10 to
2.20, 23.87 to 51.52 and 1.61 to 91.44 with means of
21.8161.09, 33.7165.15 and 33.46626.68, respectively (Figure
S1 B,C,D). NAFLD-LFS, HSI and FLI had comparable values in
LRA subjects. All indices differed between persons with and
without steatosis of the whole group (NAFLD-LFS: p,0.05; HSI:
p,0.001; FLI: p,0.01) and LRA subgroups (p,0.01; p,0.01;
p,0.05). All indices correlated with HCL and HVOL in the whole
and LRA group. HCL and indices also related to ATtot, SAT and
VAT in the whole and LRA group, except for NAFLD-LFS,
which did not correlate with ATtot and SAT (Table 2, for ATtot
and SAT data not shown).
Diagnostic performance of indices
Across all persons, AROC’s were 0.70(95% confidence interval
[0.53;0.87]) for NAFLD-LFS, 0.79[0.68;0.90] for HSI, and
0.72[0.59;0.85] for FLI (Figure 1A). In the LRA subgroup, AROC’s
were 0.75[0.57;0.92], 0.80[0.68;0.92], and 0.75[0.63;0.88], respec-
tively. AROC’s did not differ from each other in the whole and LRA
group.
Raising the threshold for diagnosing steatosis by HCL above
5.56% improved AROC’s for all indices in the whole group
(Figure 1B) and in LRA subjects (data not shown). However,
AROC of FLI did not further improve at a threshold of 7%.
Applying the originally published cut-off values for each index,
which rule in or out steatosis, yielded different diagnostic
performance. NAFLD-LFS provided low Se (0.35[0.14;0.62]),
but high Sp (0.91[0.82;0.96]). In contrast, HSI had maximal Se
(1.00[0.81;1.00]) at the lower cut-off and acceptable Sp
(0.75[0.63;0.84]) at the upper cut-off value. FLI had comparable
Se (0.76[0.50;0.93]) and Sp (0.83[0.72;0.90]). Analysis of the LRA
subgroup revealed similar results (data not shown). We also
calculated positive (PPV) and negative predictive values (NPV) of
the three indices, with NAFLD-LFS, HSI and FLI having a PPV
of 0.46[0.19; 0.75], 0.25[0.16; 0.37] and 0.31[0.18; 0.47]. NPV for
NAFLD-LFS, HSI and FLI were 0.86[0.76; 0.93], 0.88[0.77;
0.94] and 0.84[0.73; 0.91], respectively.
To determine optimal cut-off values for each index in our
sample, we identified those values that maximize Youden’s index.
In the whole sample, the optimal cut-off values were 21.02 for
NAFLD-LFS yielding a Se of 0.59[0.33; 0.82] and Sp of
0.89[0.80; 0.95], 35.0 for HSI (Se 0.76[0.50; 0.93]; Sp
0.70[0.59; 0.81]), and 29.2 for FLI (Se 0.82[0.56; 0.96]; Sp
0.61[0.49; 0.72]). In the LRA subgroup, the values were21.12 for
NAFLD-LFS (Se 0.64[0.31; 0.89]; Sp 0.87[0.75; 0.95]), 34.0 for
HSI (Se 0.91[0.59; 1.0]; Sp 0.67[0.53; 0.79]) and 29.2 for FLI
(0.91[0.59; 1.0];0.67[0.53; 0.79]).
After optimization of cut-off values, PPV were 0.56[0.31;0.79]
for NAFLD-LFS, 0.37[0.21;0.55] for HSI and 0.33[0.19;0.49] for
FLI. NPV were 0.91[0.81;0.96] for NAFLD-LFS, 0.93[0.83;0.98]
for HSI and 0.94[0.83;0.99] for FLI. For the LRA subgroup,
values were 0.77[0.48;0.95] (PPV) and 0.92[0.81;0.98] (NPV) for
NAFLD-LFS, 0.55[0.35;0.74] (PPV) and 0.97[0.86;1.0] (NPV) for
HSI, and 0.55[0.35;0.74] (PPV) and 0.97[0.86;1.0] (NPV) for FLI.
Finally, we examined whether specific indices can predict
percentage of HCL by applying the previously proposed NAFLD-
LFS_cont index using the identical parameters as NAFLD-LFS
[6]. NAFLD-LFS_cont correlated with HCL across all (r = 0.42,
p,0.001) and LRA persons (r = 0.27, p,0.05) (Figure 1C).
However, the differences between observed and predicted ln-
transformed HCL values (residuals) ranged from 23.9 to 2.5
(Figure 1D). Translated to the original scale, this means that
the ratio of observed and predicted liver fat ranges from 0.02 to
12.2.
Table 2. Correlation (R) of HCL and indices with insulin
sensitivity, b-cell function, liver volume and visceral adipose
tissue.
Variable HCL_ln NAFLD-LFS HSI FLI
Liver fat, volume and fat distribution
HCL_ln All 1 0.42*** 0.46*** 0.50***
LRA 1 0.26* 0.37** 0.43***
HVOL_ln All 0.36*** 0.38*** 0.45*** 0.52***
LRA 0.30* 0.32* 0.39** 0.48***
VAT_ln All 0.52*** 0.52*** 0.58*** 0.78***
LRA 0.47*** 0.39** 0.54*** 0.76***
Insulin sensitivity
ISIcomp_ln All 20.46*** 20.71*** 20.53*** 20.62***
LRA 20.34** 20.56*** 20.48*** 20.59***
OGIS All 20.46*** 20.51*** 20.50*** 20.62***
LRA 20.39** 20.27* 20.43*** 20.55***
QUICKI All 20.38*** 20.68*** 20.42*** 20.55***
LRA 20.24* 20.62*** 20.35** 20.46***
b-cell function
DI_ln All 0.36*** 0.57*** 0.48*** 0.47***
LRA 0.24 0.46*** 0.45*** 0.47***
B-cell func_ln All 0.28** 0.57*** 0.47*** 0.57***
LRA 0.10 0.46*** 0.45*** 0.54***
AI All 0.22* 0.35*** 0.33** 0.34***
LRA 0.14 0.25* 0.29* 0.29*
IGI_CP_ln All 0.11 0.05 0.02 20.02
LRA 0.08 0.06 0.00 20.03
IGI_Ins_ln All 0.22* 0.26* 0.19 0.16
LRA 0.15 0.25* 0.14 0.11
Hep _Extr_ln All 20.34*** 20.55*** 20.42*** 20.39***
LRA 20.24 20.46*** 20.42*** 20.39***
*, p,0.05;
**, p,0.01;
***, p,0.001;
B-cell func, B-cell function.
doi:10.1371/journal.pone.0094059.t002
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Correlation of HCL and indices with glycemia, insulin
sensitivity and b-cell function
Subjects with steatosis had similar blood glucose, but higher
insulin and C-peptide during OGTT than those without steatosis
(Figure 2 A,B). In LRA subjects, presumably due to low sample
size, differences in insulin and C-peptide levels were less
prominent (Figure 2 C,D).
HCL correlated inversely with fasting (QUICKI) and dynamic
insulin sensitivity (OGIS, ISIcomp) and positively with fasting b-
cell function and post-load insulin release (DI, AI, IGI_Ins) in all,
but not in LRA subjects (table 2).
Also, the indices inversely and strongly correlated with
QUICKI, OGIS and ISIcomp (table 2). Even after adjustment
for age, sex, and HCL (model-1, table 3) and for LRA (model-2,
table 3), FLI, NAFLD-LFS and HSI still related to all parameters
of insulin sensitivity.
In all and LRA subjects, indices correlated with fasting b-cell
function, DI and AI. Only NAFLD-LFS related to IGI_INS
(p,0.05) (table 2). Applying model-1 on all subjects, correlations
between indices and fasting b-cell function, DI and AI were still
present. Also, applying model-2, correlations remained (table 3).
LRA subjects showed comparable results with model-1, only HSI
did not correlate with AI and NAFLD-LFS was not associated
with OGIS (data not shown).
Hepatic insulin extraction differed between subjects with and
without FL (table 1) and related to HCL and indices in all
(p,0.001), but not in LRA subjects (p = 0.06). However, all indices
correlated with hepatic insulin extraction in all and LRA subjects
(table 2).
Discussion
In this non-diabetic, predominantly non-obese collective from
the general population NAFLD-LFS, HSI and FLI offer a
diagnostic efficacy of 70–80% with lower sensitivities and
specificities compared with their original description. Interestingly,
this study shows additional features of these indices as predictors of
insulin resistance and - to less extent - insulin secretion.
Several factors might contribute to the lower than expected
diagnostic efficacy of the indices, including selection and
characteristics of the study populations (inclusion criteria, risk
factor prevalence) as well as measurement technique [27]. In
contrast to the populations from which the indices were derived,
our study consists of a sample of non-diabetic, predominantly non-
obese white persons from the general population. For NAFLD-
LFS, the Finnish collective comprises persons without and with
T2DM recruited on a 3-to-1 basis for metabolic studies [6]. HSI
was derived from data of a Korean cross-sectional case-control
study [5]. Finally, FLI however, was developed from data of the
Dionysos Nutrition & Liver study, which included residents of
Campogalliano in Italy [4,31], providing a real sampling of
general population without particular bias in selection, but
development of FLI was based on equally matched persons with
and without suspected liver disease (SLD). Comparing these
collectives shows marked differences in prevalence of risk factors.
Figure 1. Performance of indices (all subjects). (A) ROC curves of NAFLD-LFS (black line), HSI (dotted line) and FLI (dashed line) (B) AROC’s of
NAFLD-LFS (black line), HSI (dotted line) and FLI (dashed line) for different HCL cut-offs defining steatosis (C) Correlation of HCL with NAFLD-LFS_cont.
Black line, linear regression curve; inner broken lines, 95% confidence limits; outer broken lines, 95% prediction limits (D) Evaluation of goodness of fit
by plotting residuals against HCL calculated by NAFLD-LFS_cont.
doi:10.1371/journal.pone.0094059.g001
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The NAFLD-LFS collective presents with already increased risk
for metabolic diseases such as T2DM due to greater BMI, BP, TG
and transaminases [6]. The HSI collective comprised exclusively
Asians, who develop NAFLD at lower BMI with 3.5fold greater
prevalence in males, both of which differing from whites [32].
Remarkably, both BMI and sex are variables of the HSI. The FLI
collective comprised a white sample of the general population, but
cases of SLD were matched with cases without SLD and therefore
prevalence of the metabolic syndrome and T2DM might not be
the same as in the general population [31].
The sensitivity of ultrasound to detect steatosis is about 91% in
patients with HCL $30% [33], but only 64% for HCL ,30%,
indicating that ultrasound misses cases of mild steatosis. Thus, HSI
and FLI, which have been validated against ultrasound, may have
been rather designed to reliably identify patients with medium to
severe fatty liver disease than those with mild steatosis. Testing the
accuracy of FLI in a smaller group of women with previous
gestational diabetes revealed a strong correlation with HCL
measured by 1H-MRS [34], whereas FLI and HSI performed less
well in patients with T2DM [8]. We found reasonable AROCs for
FLI and HSI, but lower diagnostic performance for NAFLD-LFS
in our collective. The latter might be due to the lower mean HCL
compared to the validation study of NAFLD-LFS [6]. NAFLD-
LFS_cont was derived from the NAFLD-LFS collective and
developed exclusively to predict percent HCL [6]. The present
study showed that the residuals, i.e. the differences between
observed and predicted HCL using this specific index, were in
most cases as high as the value of HCL contents. This indicates
that NAFLD-LFS_cont is not suitable for prediction of HCL at
least in non-diabetic collectives with lower prevalence of steatosis.
Thus, these scores offer overall modest performance in the clinical
setting– even after optimizing cut-off values for our collective. In
detail, sensitivity and specificity differ among the three indices
between 0.59 and 0.82 for Se and 0.61 and 0.89 for Sp,
respectively. This means that up to 41% of the investigated
individuals may be classified as patients without FL, although
having FL (false-negative rate) and up to 39% of the individuals
may be grouped as FL positive, although having no FL (false-
positive rate). These data do not support their use as screening
tools, at least for populations with similar characteristics as in the
present study with such non-obese persons. Additionally, the
positive predictive values indicate that in case of a positive test
result, the probability that the patient really has FL is only between
33 and 56%. It might be also critical to adjust cut-offs for FL
indices for the tested cohort. Nevertheless, the acceptable
correlation between fatty liver indices and exact quantification of
HCL suggests that these indices might be appropriate surrogate
parameters of liver fat content in large epidemiological studies. It is
well accepted that hepatic steatosis associates with insulin
resistance and hyperinsulinemia even in lean glucose-tolerant
subjects [7]. Likewise, FLI correlates with insulin resistance and
T2DM incidence [7,34,35]. Although NAFLD-LFS also predicted
T2DM in a French cohort [36], its relationship with insulin
resistance has not been assessed. To our knowledge, HSI has also
not been analyzed with regard to insulin sensitivity and secretion.
Here we clearly show that all three indices, strongly and inversely
correlate with measures of insulin sensitivity.
Figure 2. OGTT in subjects with and without steatosis. Plasma glucose (all: A, LRA: B), insulin and C-peptide (all: C, LRA: D) during OGTT in
subjects without (non-FL) (insulin: open triangles, C-peptide: black triangles) and with steatosis (FL) (insulin: open circles, C-peptide: black squares). *,
p,0.05; **, p,0.01 for insulin; 1, p,0.05 for C-peptide.
doi:10.1371/journal.pone.0094059.g002
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Of note, less is known on an association between HCL and b-
cell function. While HCL and fasting insulin may correlate [37],
data on its relationship with dynamic/OGTT postload b-cell
function in collectives with normal and impaired glucose tolerance
was contradictory [38,39]. Here, we confirm that HCL relates to
various parameters of b-cell function except IGI in all, but not in
LRA subjects, and extend this finding to the three indices. The
indices only failed to associate with IGI_Ins and IGI_CP, which
might result from the pre-described rather low performance of IGI
in small- to medium-sized collectives [21].
The novelty of the present study resides in the direct
comparison of different indices with HCL measurement by 1H-
MRS in a single study population of non-diabetic, predominantly
non-obese whites and the finding that - while not specific for
prediction of hepatic steatosis - they at least partly reflect glucose
homeostasis. On the other hand, this study has also certain
limitations. First, this study has a rather small sample size and a
collective with low mean HCL contents and prevalence of
steatosis. This should not influence Se and Sp of the indices [27]
and increases the relevance of these results for general screening of
steatosis. However, the predominance of persons with low HCL
contents might contribute to the wide confidence intervals for
sensitivity and the low positive predictive values thereby under-
estimating the value of the indices. The small sample size may also
add to the wide confidence intervals for AROCs of the tested
indices. Moreover, when comparing AROCs of the different
indices, we did not find significant differences in performances, but
we cannot fully exclude that there might be differences in
performance we cannot detect with our collective. Thus, further
validation of these indices should be performed in larger cohorts.
Second, participants with significant consumption of alcohol
were not omitted from the analysis of the whole collective, as the
relative contribution of ethanol intake to the pathogenesis of
NAFLD is still uncertain [4]. In their regression models, Bedogni
et al. even report no association between ethanol intake and
steatosis [4]. Recent data suggest that - despite the potential
interactions between alcohol drinking and liver injury - moderate
alcohol intake may have paradoxical, favorable and gender-
dependent effects also in the liver [40,41]. However, as heavy
drinking is known for its deleterious effects on the liver, we set
maximum acceptable alcohol intake to 40 g/d for men and 20 g/
d for women, which is below the levels set for heavy drinking
(.60 g/d for men and .40 g/d for women), for analyses of the
LRA subgroup. Of note, all analyses were also performed in this
LRA subgroup, which gave similar results as reported for the
whole group.
In conclusion, the tested fatty liver indices offer modest efficacy
to detect steatosis and cannot substitute for exact fat quantification
by 1H-MRS. However, they might serve as surrogate parameters
for liver fat content and also as rough clinical estimates of
abnormal insulin sensitivity and secretion. Further validation in
larger collectives such as epidemiological studies is needed.
Supporting Information
Figure S1 Comparison of HCL and indices in subjects
with and without steatosis. Box plots of HCL (A), NAFLD-
LFS (B), HSI (C) and FLI (D) scores.
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Table 3. Association of indices with insulin sensitivity and b-cell function after adjustment for age, sex, HCL and LRA.
Model-1 Age,Sex,HCL Model-2 Age,Sex,HCL,LRA
Dependent Estimate (b) Partial correlation Estimate (b) Partial correlation
NAFLD-LFS All OGIS 222.3*** 20.38 222.9*** 20.39
HSI 24.1** 20.35 24.3*** 20.35
FLII 220.4*** 20.46 221.1*** 20.46
NAFLD-LFS QUICKI 20.03*** 20.62 20.03*** 20.64
HSI 20.003** 20.32 20.003** 20.33
FLII 20.02*** 20.45 20.02*** 20.46
NAFLD-LFS ISIcomp_ln 20.31*** 20.64 20.33*** 20.66
HSI 20.04*** 20.41 20.04*** 20.42
FLII 20.19*** 20.51 20.20*** 20.52
NAFLD-LFS Disposition Index_ln 0.22*** 0.52 0.23*** 0.55
HSI 0.03*** 0.38 0.04*** 0.40
FLII 0.13*** 0.41 0.14*** 0.43
NAFLD-LFS Adaptation Index 0.04*** 0.34 0.04*** 0.36
HSI 0.006* 0.24 0.006* 0.24
FLII 0.03** 0.32 0.03** 0.33
NAFLD-LFS B-cell func_ln 0.21*** 0.53 0.19*** 0.53
HSI 0.03*** 0.40 0.03*** 0.40
FLII 0.16*** 0.56 0.16*** 0.56
*, p,0.05;
**, p,0.01;
***, p,0.001;
B-cell func, B-cell function.
doi:10.1371/journal.pone.0094059.t003
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